Digital Look

Welcome to Digital Look++,
you are not logged in

Allergy Therapeutics (AGY)

Pharma and Biotech

6.45p

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue (£m)	Pre-tax (£m)	EPS	Dividend
31-Dec-24	Interim	34.03	(11.36)	(0.23)p	n/a

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
30-Jun-20	78.20	8.07	1.11p	12.6	0.1	+102%	n/a	0.0%
30-Jun-21	84.33	3.66	0.45p	55.6	n/a	-60%	n/a	0.0%
30-Jun-22	72.77	(12.66)	(2.14)p	n/a	n/a	n/a	n/a	0.0%
30-Jun-23	59.59	(41.77)	(6.43)p	n/a	n/a	n/a	n/a	0.0%
30-Jun-24	55.20	(39.17)	(1.07)p	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
30-Jun-25	64.80	(23.10)	(0.66)p	n/a	n/a	n/a	n/a	0.0%
30-Jun-26	80.90	(9.70)	(0.40)p	n/a	n/a	n/a	n/a	0.0%

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	12.61	n/a	10.68	0

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.